Manufacturer: Cipla, India
Pharmaceutical name: Dorzolamide
Pack: 1 bottle (5 ml (2% ))
Dorzox is an ophthalmic solution designed to treat glaucoma and ocular hypertension. It contains dorzolamide, a potent ingredient that works as a carbonic anhydrase inhibitor to lower elevated intraocular pressure. Additionally, it can be classified as a topical beta blocker.
Dorzox is typically prescribed for patients with glaucoma and ocular hypertension. Ocular hypertension, characterized by increased intraocular pressure, poses a significant risk for glaucoma development, which can damage the optic nerve and lead to blindness. Dorzolamide, the primary active ingredient in Dorzox, belongs to the category of beta blockers and carbonic anhydrase inhibitors. Its therapeutic effect is achieved by inhibiting carbonic anhydrase, thereby decreasing fluid secretion, lowering intraocular pressure, reducing the risk of optic nerve damage, and preventing vision loss.
Dorzox eye drops are effective for managing elevated eye pressure associated with ocular hypertension and open-angle glaucoma, both of which can cause eye pain and threaten vision. Recommended dosage is 1-2 drops, applied two or three times daily.
Patients using Dorzox may experience side effects, including blurred vision, eye itching and irritation, severe headaches, a bitter taste in the mouth, and feelings of eye fatigue.